RecruitingPhase 2NCT07399704
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
Studying GM2 gangliosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Azafaros A.G.
- Intervention
- AZ-3102(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2026 – 2030
Study locations (3)
- Associação Hospitalar de Prot à Infância Dr. Raul Carneiro, Água Verde, Curitiba, Brazil
- Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Rio de Janeiro, Brazil
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07399704 on ClinicalTrials.govOther trials for GM2 gangliosidosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT06614569Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff DiseaseTerence Flotte
- ACTIVE NOT RECRUITINGPHASE2NCT05758922Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C DiseaseAzafaros A.G.
- RECRUITINGNCT05007990Caregiving Networks Across Disease Context and the Life CourseNational Human Genome Research Institute (NHGRI)